<SEC-DOCUMENT>0001609492-26-000006.txt : 20260512
<SEC-HEADER>0001609492-26-000006.hdr.sgml : 20260512
<ACCEPTANCE-DATETIME>20260512195622
ACCESSION NUMBER:		0001609492-26-000006
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260512
DATE AS OF CHANGE:		20260512

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Werewolf Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001785530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				823523180
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-92515
		FILM NUMBER:		26970438

	BUSINESS ADDRESS:	
		STREET 1:		200 TALCOTT AVENUE
		STREET 2:		2ND FLOOR
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		617-952-0555

	MAIL ADDRESS:	
		STREET 1:		200 TALCOTT AVENUE
		STREET 2:		2ND FLOOR
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MPM BioVentures 2014, L.P.
		CENTRAL INDEX KEY:			0001609492
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		C/O MPM BIOIMPACT
		STREET 2:		399 BOYLSTON STREET, SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(617) 425-9200

	MAIL ADDRESS:	
		STREET 1:		C/O MPM BIOIMPACT
		STREET 2:		399 BOYLSTON STREET, SUITE 1100
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
		<previousAccessionNumber>0001609492-26-000004</previousAccessionNumber>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001609492</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
		<amendmentNo>7</amendmentNo>
	      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <dateOfEvent>05/08/2026</dateOfEvent>
	  <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001785530</issuerCIK>

		<issuerCusips>
					<issuerCusipNumber>95075A107</issuerCusipNumber>
				</issuerCusips>

		<issuerName>WEREWOLF THERAPEUTICS, INC.</issuerName>

        <address>
          <com:street1>200 TALCOTT AVENUE</com:street1>
          <com:street2>2ND FLOOR</com:street2>          <com:city>WATERTOWN</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02472</com:zipCode>
        </address>
      </issuerInfo>

	  	  <authorizedPersons>

		<notificationInfo>
			<personName>Ansbert Gadicke</personName>
			<personPhoneNum>617-425-9200</personPhoneNum>
				<personAddress>
					<com:street1>c/o MPM BioImpact LLC</com:street1>
					<com:street2>339 Boylston Street, Suite 1100</com:street2>					<com:city>Boston</com:city>
					<com:stateOrCountry>MA</com:stateOrCountry>
					<com:zipCode>02116</com:zipCode>
				</personAddress>
		</notificationInfo>
			</authorizedPersons>
	    </coverPageHeader>

	<reportingPersons>


			<reportingPersonInfo>
									<reportingPersonCIK>0001609492</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM BioVentures 2014, L.P. </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>792254.00</soleVotingPower>
												<sharedVotingPower>0.00</sharedVotingPower>
												<soleDispositivePower>792254.00</soleDispositivePower>

				<sharedDispositivePower>0.00</sharedDispositivePower>
												<aggregateAmountOwned>792254.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.6</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>









			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001609493</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM BioVentures 2014 (B), L.P. </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>52840.00</soleVotingPower>
												<sharedVotingPower>0.00</sharedVotingPower>
												<soleDispositivePower>52840.00</soleDispositivePower>

				<sharedDispositivePower>0.00</sharedDispositivePower>
												<aggregateAmountOwned>52840.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>0.1</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>









			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001609495</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM Asset Management Investors BV2014 LLC </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>27267.00</soleVotingPower>
												<sharedVotingPower>0.00</sharedVotingPower>
												<soleDispositivePower>27267.00</soleDispositivePower>

				<sharedDispositivePower>0.00</sharedDispositivePower>
												<aggregateAmountOwned>27267.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>0.1</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>



			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001691428</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>UBS Oncology Impact Fund L.P. </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>E9</citizenshipOrOrganization>
												<soleVotingPower>655471.00</soleVotingPower>
												<sharedVotingPower>0.00</sharedVotingPower>
												<soleDispositivePower>655471.00</soleDispositivePower>

				<sharedDispositivePower>0.00</sharedDispositivePower>
												<aggregateAmountOwned>655471.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.3</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>









			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001765091</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM BioVentures 2014 GP LLC </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>845094.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>845094.00</sharedDispositivePower>
												<aggregateAmountOwned>845094.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.7</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>



			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001765021</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM BioVentures 2014 LLC </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>872361.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>872361.00</sharedDispositivePower>
												<aggregateAmountOwned>872361.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.8</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>



			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001721036</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Oncology Impact Fund (Cayman) Management L.P. </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>E9</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>655471.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>655471.00</sharedDispositivePower>
												<aggregateAmountOwned>655471.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.3</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>









			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001687078</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM BioImpact LLC </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>655471.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>655471.00</sharedDispositivePower>
												<aggregateAmountOwned>655471.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.3</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>



			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001134655</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>ANSBERT GADICKE</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>X1</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>1826646.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>1826646.00</sharedDispositivePower>
												<aggregateAmountOwned>1826646.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>3.8</percentOfClass>











			  			  <typeOfReportingPerson>IN</typeOfReportingPerson>




			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001134657</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>LUKE EVNIN</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>X1</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>1171175.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>1171175.00</sharedDispositivePower>
												<aggregateAmountOwned>1171175.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>2.4</percentOfClass>











			  			  <typeOfReportingPerson>IN</typeOfReportingPerson>




			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001473930</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Todd Foley</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>X1</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>872361.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>872361.00</sharedDispositivePower>
												<aggregateAmountOwned>872361.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.8</percentOfClass>











			  			  <typeOfReportingPerson>IN</typeOfReportingPerson>




			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001263048</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM ASSET MANAGEMENT LLC </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>125480.00</soleVotingPower>
												<sharedVotingPower>0.00</sharedVotingPower>
												<soleDispositivePower>125480.00</soleDispositivePower>

				<sharedDispositivePower>0.00</sharedDispositivePower>
												<aggregateAmountOwned>125480.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>0.3</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>



			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001719960</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM ONCOLOGY INNOVATIONS FUND LP </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>173334.00</soleVotingPower>
												<sharedVotingPower>0.00</sharedVotingPower>
												<soleDispositivePower>173334.00</soleDispositivePower>

				<sharedDispositivePower>0.00</sharedDispositivePower>
												<aggregateAmountOwned>173334.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>0.4</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>









			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001857903</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>MPM Oncology Innovations Fund GP LLC </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>173334.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>173334.00</sharedDispositivePower>
												<aggregateAmountOwned>173334.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>0.4</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>



			</reportingPersonInfo>
			</reportingPersons>


	<items1To7>
		<item1>
			<securityTitle>Common Stock</securityTitle>
			<issuerName>WEREWOLF THERAPEUTICS, INC.</issuerName>

			<issuerPrincipalAddress>
			 <com:street1>200 TALCOTT AVENUE</com:street1>
			  <com:street2>2ND FLOOR</com:street2>			  <com:city>WATERTOWN</com:city>
			  <com:stateOrCountry>MA</com:stateOrCountry>
			  <com:zipCode>02472</com:zipCode>
			</issuerPrincipalAddress>

						<commentText>Explanatory Note:  This Amendment No. 7 to Schedule 13D ("Amendment No. 7") is being filed as an amendment to the initial statement on Schedule 13D relating to the common stock (the "Common Stock"), of Werewolf Therapeutics Inc. (the 'Issuer'), as filed with the Securities and Exchange Commission (the "SEC") on May 14, 2021 and as amended by Amendment No. 1 filed November 4, 2025, Amendment No. 2 filed November 17, 2025, Amendment No. 3 filed December 3, 2025, Amendment No. 4 filed December 29, 2025, Amendment No. 5 filed January 16, 2026 and Amendment No. 6 filed May 5, 2026 (as amended, the "Original Schedule 13D").   This Schedule 13D/A is being filed by the Filing Persons to report the open market sales of the Issuer's Common Stock by certain Filing Persons.

Items 5 and 7 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect.  All capitalized terms used in this Amendment No. 7 but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.
</commentText>
					</item1>




				<item5>
			 <percentageOfClassSecurities>See rows (11) and (13) of the Filing Persons Owner Profile of this Amendment No. 7 for the aggregate number of Common Stock and percentages of the shares of Common Stock beneficially owned by the Filing Person.

The Common Stock is held as follows:

*	 792,254 shares are held directly by BV 2014;
*	  52,840 shares are held directly by BV 2014(B);
*	  27,267 shares are held directly by AM BV2014 LLC;
*	 173,334 shares are held directly by MPM OIF;
*        125,480 shares by AM LLC; and
*	  655,471 shares are held directly by UBS Oncology.

BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B) and, accordingly, may be deemed to beneficially own the shares held by BV 2014 and BV 2014(B).

BV 2014 LLC is the managing member of AM BV2014 LLC and, accordingly, may be deemed to beneficially own the shares held by AM BV2014 LLC.

MPM OIF GP is the general Partner of MPM OIF and, accordingly, may be deemed to beneficially own the shares held by MPM OIF.

BioImpact and Oncology Cayman are the direct and indirect general partners of UBS Oncology and, accordingly, may be deemed to beneficially own the shares held by UBS Oncology.

Drs. Gadicke and Evnin and Mr. Foley are the managing directors of BV 2014 LLC and, accordingly, may be deemed to beneficially own the shares held by BV 2014, BV 2014(B) and AM BV2014 LLC.

Drs. Gadicke and Evnin are the members of AM LLC and managers of MPM OIF GP and, accordingly, may be deemed to beneficially own the shares held by AM LLC and MPM OIF.

Dr. Gadicke is the managing partner of BioImpact and, accordingly may be deemed to beneficially own the shares held by UBS Oncology.

Calculation of the percentage of the shares of Common Stock beneficially owned is based upon 48,596,817 shares of Common Stock outstanding as of May 1, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 7, 2026.
</percentageOfClassSecurities>			<numberOfShares>See rows (7) through (10) of the Filing Persons Owner Profile of this Amendment No. 7 for the number of shares as to which there is sole power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition.</numberOfShares>			<transactionDesc>The Reporting Persons sold the following Common Stock in the open market since Amendment No. 6:

Date of     Price Range    Ave. Price    Sold by       Sold by      Sold By        Sold by       Sold by      Sold by
 Sale                                                    BV 2014        BV        AM BV2014   MPM OIF    AM LLC        UBS
                                                                              2014(B)         LLC                                               Oncology
05/06/26    $0.65-$0.7054        $0.66     9,900          660            341             2,166          1,568           8,190
05/07/26    $0.62-$0.667          $0.63   53,499       3,568         1,841            11,705         8.473         44,262
05/08/26    $0.6183-$0.7668    $0.70 206,820     13,795         7,119            45,250        32,757      171,114
05/11/26    $0.66-$0.7002        $0.67   22,965        1,532           790              5,024          3,637        19,000
05/12/26    $0.6286-$0.66        $0.64   45,921        3,063        1,581            10,047          7,273        37,994
</transactionDesc>			<listOfShareholders> Inapplicable.</listOfShareholders>			<date5PercentOwnership>May 8, 2026</date5PercentOwnership>		</item5>


				<item7>
			<filedExhibits>Exhibit 99.C - Joint Filing Statement</filedExhibits>
		</item7>

	</items1To7>

<signatureInfo>

	<signaturePerson>
		<signatureReportingPerson>MPM BioVentures 2014, L.P. </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014, L.P.</title>
				<date>05/12/2026</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>MPM BioVentures 2014 (B), L.P. </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Director of MPM BioVentures 2014 LLC, Managing Member of MPM BioVentures 2014 GP LLC, the General Partner of MPM BioVentures 2014 (B), L.P.</title>
				<date>05/12/2026</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>MPM Asset Management Investors BV2014 LLC </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC</title>
				<date>05/12/2026</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>UBS Oncology Impact Fund L.P. </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Partner of MPM BioImpact LLC, the GP of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P.</title>
				<date>05/12/2026</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>MPM BioVentures 2014 GP LLC </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Director of MPM BioVentures 2014 LLC, the Managing Member of MPM BioVentures 2014 GP LLC</title>
				<date>05/12/2026</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>MPM BioVentures 2014 LLC </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Director</title>
				<date>05/12/2026</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>Oncology Impact Fund (Cayman) Management L.P. </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Partner of MPM BioImpact LLC, the General Partner of Oncology Impact Fund (Cayman) Management L.P.</title>
				<date>05/12/2026</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>MPM BioImpact LLC </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Managing Partner</title>
				<date>05/12/2026</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>ANSBERT GADICKE</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Ansbert Gadicke</title>
				<date>05/12/2026</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>LUKE EVNIN</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Luke Evnin</signature>
				<title>Luke Evnin</title>
				<date>05/12/2026</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>Todd Foley</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Todd Foley</signature>
				<title>Todd Foley</title>
				<date>05/12/2026</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>MPM ASSET MANAGEMENT LLC </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Member</title>
				<date>05/12/2026</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>MPM ONCOLOGY INNOVATIONS FUND LP </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Manager of MPM Oncology Innovations Fund GP LLC, the General Partner of MPM Oncology Innovations Fund, L.P.</title>
				<date>05/12/2026</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>MPM Oncology Innovations Fund GP LLC </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Ansbert Gadicke</signature>
				<title>Manager</title>
				<date>05/12/2026</date>
			</signatureDetails>

	</signaturePerson>



</signatureInfo>
</formData>



</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.C
<SEQUENCE>2
<FILENAME>ex-99-05122026_110506.htm
<DESCRIPTION>EXHIBIT 99.C - JOINT FILING STATEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//IETF//DTD HTML//EN">
<html><head><title>ex-99-05122026_110506.htm</title></head><body style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<p style="margin:0px; font-size:11pt" align="center"><b>Joint Filing Statement</b></p>
<p style="margin:0px"><br></p>
<p style="margin:0px; padding-left:48px; padding-right:-6px; text-indent:52.8px; font-size:11pt" align="justify">I, the undersigned, hereby express my agreement that the attached Schedule&nbsp;13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Werewolf Therapeutics, Inc. is filed on behalf of each of the undersigned.</p>
<p style="margin:0px"><br></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Date: May 12, 2026</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>MPM BioVentures 2014, L.P.</b></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM BioVentures 2014 GP LLC, </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;its General Partner</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM BioVentures 2014 LLC, </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its Managing Member</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Director</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>MPM BioVentures 2014 (B), L.P.</b></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM BioVentures 2014 GP LLC, </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;its General Partner</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM BioVentures 2014 LLC, </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its Managing Member</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Director</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>MPM Asset Management Investors BV 2014 LLC</b></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: MPM BioVentures 2014 LLC</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its: Manager</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Director</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>MPM BioVentures 2014 GP, LLC</b></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM BioVentures 2014 LLC, </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its Managing Member</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Director</p>
<p style="margin-top:0px; margin-bottom:16px"><br></p>
<p style="margin-top:0px; margin-bottom:13.333px"><br></p>
<p style="margin-top:0px; margin-bottom:16px"><br><br></p>
<hr style="margin-bottom: 9.6px; padding-top: 9.6px;" noshade size="1"><p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt; page-break-before:always"><b>MPM BioVentures 2014 LLC</b></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Director</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>MPM Asset Management LLC</b></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Member</p>
<p style="margin-top:0px; margin-bottom:16px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>MPM Oncology Innovations Fund LP</b></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM Oncology Innovations Fund GP LLC </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;its General Partner</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Manager</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>MPM Oncology Innovations Fund GP LLC</b></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Manager</p>
<p style="margin-top:0px; margin-bottom:16px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>UBS Oncology Impact Fund, L.P.</b></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;Oncology Impact Fund (Cayman) Management L.P., </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;its General Partner</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM BioImpact LLC, </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its General Partner</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Partner</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:13.333px"><br></p>
<p style="margin-top:0px; margin-bottom:16px"><br><br></p>
<hr style="margin-bottom: 9.6px; padding-top: 9.6px;" noshade size="1"><p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt; page-break-before:always"><b>Oncology Impact Fund (Cayman) Management L.P.</b></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">By: &nbsp;MPM BioImpact LLC, </p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Its General Partner</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Partner</p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:16px; padding-left:48px; padding-right:67.2px; font-size:11pt"><b>MPM BioImpact LLC</b></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Managing Partner</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Todd Foley</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Todd Foley</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Luke Evnin</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Luke Evnin</p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin-top:0px; margin-bottom:-2px; text-indent:48px; width:114px; font-size:11pt; float:left">By:</p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; text-indent:-2px; font-size:11pt"><u>/s/ Ansbert Gadicke</u></p>
<p style="margin:0px; padding-left:48px; padding-right:67.2px; font-size:11pt; clear:left">Name: &nbsp;&nbsp;Ansbert Gadicke</p>
<p style="margin-top:0px; margin-bottom:16px"><br></p>
<p style="margin:0px"><br></p>
<p style="margin:0px"><br><br></p>
</body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
